Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CFD | P00746 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31439507 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL10501327 | 0.86 | KMT2A (0.83) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL10911824 | 0.85 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL16404495 | 0.85 | KMT2A (0.69) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL6691248 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL31541283 | 0.84 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL10814639 | 0.84 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL4011016 | 0.84 | ALDH1A1 (0.65) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL10914318 | 0.84 | ALDH1A1 (0.66) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL138820 | 0.83 | KMT2A (0.72) | ALDH1A1KMT2AMEN1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8119918-A | — | — | None | — | — | JP | disclosed |
| US-20250145617-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | WASHINGTON UNIVERSITY | 2025-05-08 | — | — | US | disclosed |
| WO-2025015167-A2 | ERASTIN KETONE ANALOGS AND USES THEREOF | EXARTA THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | UNIV NOTTINGHAM (GB) | 2022-08-09 | — | — | US | disclosed |
| CN-108201625-B | Linker drugs and antibody drug complexes comprising the same | 财团法人工业技术研究院 | 2022-06-07 | — | — | CN | disclosed |
| CN-114026063-A | Bis (2-haloacetamido) -compounds useful as linkers and resulting products comprising antibodies, half-antibodies and antibody fragments | 巴斯大学 | 2022-02-08 | — | — | CN | disclosed |
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210221805-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | WASHINGTON UNIVERSITY | 2021-07-22 | — | — | US | disclosed |
| JP-H08119918-A | MIXED POLYVALENT METAL SALT, POLYVALENT METAL SALT COMPOSITION CONTAINING THE SAME AND RECORDING MATERIAL | MITSUI TOATSU CHEM INC | 1996-05-14 | — | — | JP | disclosed |
| EP-0292846-B1 | A process for the extraction of docosahexaenoic acid ethyl ester from fish oils and pharmaceutical and/or dietetic compositions containing a mixture of docosahexaenoic and eicosapentaenoic acid ethyl esters | STAR OIL LTD (GB) | 1994-08-17 | — | — | EP | disclosed |
| US-5217961-A | High carcinostatic activity; inhibiting KB-cell growth | MECT CORPORATION (JP) | 1993-06-08 | — | — | US | disclosed |
| US-4977258-A | Benzoxazepinone process | MERCK, SHARP & DOHME LTD. (GB) | 1990-12-11 | — | — | US | disclosed |
| EP-0376166-A1 | Condensed quinoline system compound and process of preparation thereof | MECT CORPORATION (JP) | 1990-07-04 | — | — | EP | disclosed |
| EP-0362942-A2 | Benzoxazepinone process | MERCK SHARP & DOHME LTD. (GB) | 1990-04-11 | — | — | EP | disclosed |
| EP-0292846-A2 | A process for the extraction of docosahexaenoic acid ethyl ester from fish oils and pharmaceutical and/or dietetic compositions containing a mixture of docosahexaenoic and eicosapentaenoic acid ethyl esters | STAR OIL LTD (GB) | 1988-11-30 | — | — | EP | disclosed |
| US-4187306-A | Benzodiazepine-diones, a process for their production and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1980-02-05 | — | — | US | disclosed |
| US-4183931-A | SEDATIVE-HYPNOTICS, ANTICONVULSANTS, CENTRAL NERVOUS SYSTEM DEPRESSANTS | RESEARCH CORPORATION (US) | 1980-01-15 | — | — | US | disclosed |
| EP-0000538-A1 | 6,7-Dihydro-5H,13H-quinazolino(3,2-a)(1,4)benzodiazepine-5,13-diones, process for their preparation and their use as medicaments. | BAYER AG (DE) | 1979-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221805-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | SIGMAR1, TMEM97, AIFM2 | ALDH1A1 1104/4885KMT2A 3212/4885MEN1 3626/4885 |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | CDK1, CDK11A, CDK12 | ALDH1A1 4568/4885KMT2A 454/4885MEN1 1864/4885 |
| US-20250145617-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | SIGMAR1, TMEM97, AIFM2 | ALDH1A1 1104/4885KMT2A 3212/4885MEN1 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.